Our patented and proprietary siRNA formulation is designed for high-efficiency gene silencing with enhanced targeted delivery and stability. Using polymeric nanoparticles, we encapsulate siRNA molecules to improve cellular uptake and achieve sustained therapeutic effects.
Protects siRNA from enzymatic degradation, extending its systemic half-life.
Functionalized nanocarriers ensure precise localization to tumor or disease-affected cells.
Prolonged gene silencing with optimized dosing intervals.
Engineered to evade immune response, ensuring safety.
Our hydrogel-based siRNA system targets PLK1, a key regulator of tumor cell proliferation. Unlike lipid-based carriers, our chitosan-derived hydrogel nanoparticles provide greater
Selectively inhibits PLK1, inducing tumor apoptosis.
Efficient nanoparticle penetration for improved bioavailability.
Demonstrated tumor suppression with minimal toxicity in in vivo models.
We harness the power of RNAi and nanomedicine to develop innovative cancer treatment delivery systems.
Our treatments undergo comprehensive preclinical studies, ensuring efficacy and safety.
We design therapies that prioritize biocompatibility, controlled release, and minimal systemic toxicity.
We adhere to the highest standards in scientific integrity, safety, and regulatory compliance.
Nanora Pharma is at the forefront of pharmaceutical innovation, dedicated to developing advanced treatments that improve lives worldwide. Our passion for science and commitment to health drive us to deliver groundbreaking solutions for today’s medical challenges.
